書籍情報から探す
A RANDOMIZED CONTROLLED TRIAL TO INVESTIGATE DWELL TIME OF SINGLE IMMEDIATE AND ADDITIONAL ADJUVANT INTRAVESICAL CHEMOTHERAPY WITH PIRARUBICIN FOR NON-MUSCLE-INVASIVE BLADDER CANCER FOLLOWING TRANSURETHRAL RESECTION OF BLADDER TUMOR
YOSHIAKI KAWANO1), RYOMA KURAHASHI1), TAKANOBU MOTOSHIMA1), KENICHIRO TANOUE1), JUNJI YATSUDA1), YOJI MURAKAMI1), TAKAHIRO YAMAGUCHI1), MASATOSHI ETO1), YUTAKA SUGIYAMA2), HIDEO HIRAYAMA3), SHOJI FUJISAWA4), JUN MORINAGA5), ON BEHALF OF THE KUMAMOTO BLADDER CANCER STUDY GROUP
1)Department of Urology, Faculty of Life Sciences, Kumamoto University, 2)Kidney Disease and Dialysis Center, Kumamoto University Hospital, 3)Hirayama Urology Clinic, 4)Tamana Urological Clinic, 5)Department of Clinical Investigation, Kumamoto University Hospital
The Nishinihon Journal of Urology 82 (5) 497-507, 2020.
1)Department of Urology, Faculty of Life Sciences, Kumamoto University, 2)Kidney Disease and Dialysis Center, Kumamoto University Hospital, 3)Hirayama Urology Clinic, 4)Tamana Urological Clinic, 5)Department of Clinical Investigation, Kumamoto University Hospital
The Nishinihon Journal of Urology 82 (5) 497-507, 2020.
- アブストラクト: 従量制は110円(税込)、基本料金制は基本料金に含まれます。
- 全文ダウンロード: 従量制、基本料金制の方共に770円(税込) です。
排尿障害を伴う全周性尿道憩室に対して外科的治療を行った1例
常染色体優性多発性嚢胞腎 (ADPKD) を原疾患とした先行的腎移植予定患者でミトコンドリア脳筋症 (MELAS) 併発を認め一旦血液透析導入後生体腎移植を施行した1例